Alamar Biosciences affiliate proposes $987K share sale

The notice lists 69,392,766 common shares outstanding alongside the proposed sale’s $987,000 aggregate market value.

Rhea-AI Filing Summary

Alamar Biosciences, Inc. (ALMR) is the issuer whose affiliate, Qiming Managing Directors Fund VI, L.P., reported a proposed sale of 41,945 common shares through J.P. Morgan Securities LLC. The notice lists an aggregate market value of $987,000 and an approximate sale date of October 14, 2026. It lists 69,392,766 common shares outstanding. The listed acquisition records cite private investments in Series A-3, Series A-4 and Series B preferred shares, automatically converted into common stock upon IPO.

Key Figures

Common shares proposed for sale: 41,945 shares Aggregate market value: $987,000 Common shares outstanding: 69,392,766 shares

3 metrics

Common shares proposed for sale 41,945 shares Proposed sale

Aggregate market value $987,000 Proposed sale

Common shares outstanding 69,392,766 shares Number listed in the notice

Key Terms

affiliate, par value, preferred shares, automatically converted into common stock upon IPO

4 terms

affiliate regulatory

"Affiliate"

par value financial

"Common stock, par value $0.0001 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

preferred shares financial

"Private investment in Series A-3 preferred shares"

Preferred shares are a type of investment that gives investors priority over common shareholders when it comes to receiving dividends and getting their money back if a company is sold or liquidated. Think of them as a safer, more predictable way to earn income from a company's profits, similar to a fixed-return investment, but without voting rights. This makes preferred shares appealing to those seeking stable income with a higher claim on assets than regular stockholders.

automatically converted into common stock upon IPO financial

"automatically converted into common stock upon IPO"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ALMR shares does Qiming Managing Directors Fund VI, L.P. plan to sell?

Qiming Managing Directors Fund VI, L.P. reported a proposed sale of 41,945 ALMR common shares, with an aggregate market value of $987,000. The notice lists J.P. Morgan Securities LLC as broker and October 14, 2026 as the approximate sale date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/14/2026 - 08:15 PM EDT Accepted by SEC EDGAR 10/14/2026 - 08:15 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001733282
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Alamar Biosciences, Inc.
SEC File Number	001-43235
Address of Issuer	47071 BAYSIDE PARKWAY FREMONT CALIFORNIA 94538
Phone	510-626-9888
Name of Person for Whose Account the Securities are To Be Sold	Qiming Managing Directors Fund VI, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock, par value $0.0001 per share	J.P. Morgan Securities LLC 270 Park Avenue New York NY 10117	41945	987000.00	69392766	10/14/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	05/27/2020	Private investment in Series A-3 preferred shares, automatically converted into common stock upon IPO	Issuer			71268	05/26/2020	Check
Common stock	04/30/2021	Private investment in Series A-4 preferred shares, automatically converted into common stock upon IPO	Issuer			63864	04/30/2021	Check
Common stock	08/20/2021	Private investment in Series B preferred, automatically converted into common stock upon IPO	Issuer			50031	08/18/2021	Check

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/14/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ho Man Lam
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)